BloodThinnerHelp.com reports on a recently filed Xarelto lawsuit which is quite different from most. The suit, which was filed on October 8th of 2015 against Bayer AG and Janssen Pharmaceuticals, alleges that Xarelto failed to prevent a stroke, because the drug did not last for an entire 24-hours as the package information indicates. While many have alleged that the once-daily dosage is not enough, this particular suit is notable as it provides supporting evidence of this factor. The plaintiff involved suffered a stroke just four days after starting Xarelto in order to prevent strokes due to his atrial fibrillation.
In details of his complaint, the plaintiff alleges that the blood-thinning drug was ineffective in preventing his stroke, and may have even caused the occurrence. Today, Xarelto is the subject of over 2,200 lawsuits in federal court. These suits similarly allege that Xarelto causes increased risk for uncontrollable bleeding episodes.
The United States Food and Drug Administration approved Xarelto in 2011. The pill was designed to prevent strokes and blood clots for patients who were recovering from hip and knee surgery or patients who had atrial fibrillation, a common heart condition. Initially, Xarelto was popular due to the fact that, unlike other blood thinners, it did not require special diets or regular monitoring.
No corresponding antidote
Many allegations in current Xarelto lawsuits have brought to light a major problem, which is that it was released to market with no corresponding antidote. Four years later,manufacturers have yet to provide one. Individuals using the drug who are injured and begin to bleed will be unable to get their blood to clot. Physicians treating them will have to resort to life-saving measures, such as blood transfusions or surgery to remove pressure and pooling blood.
Traditional blood thinners, quite differently, have an available antidote in vitamin K. If someone using this type of blood thinner begins to bleed, doctors can treat them with vitamin K, reversing the effects of the medication and clotting their blood. These blood thinners also require two doses of medicine daily, which the plaintiff in this particular lawsuit alleges may have prevented his stroke.
Xarelto bleeding lawsuits have been consolidated to form multidistrict litigation number 2592.They are being overseen by U.S. District Judge Eldon E. Fallon, and, at this time, bellwether trials for the cases are expected to begin in August of 2016.